Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin.
Bertamini, L., Nanni, J., Marconi, G., Abbenante, M., Robustelli, V., Bacci, F., et al. (2018). Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia. BMC CANCER, 18(1), 1-5 [10.1186/s12885-018-5026-x].
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia
Bertamini, Luca;Nanni, Jacopo;Marconi, Giovanni;Abbenante, Mariachiara;Robustelli, Valentina;Matti, Antonella;Paolini, Stefania;Sartor, Chiara;Monaco, Silvia Lo;Fontana, Maria Chiara;Cavo, Michele;Curti, Antonio;Martinelli, Giovanni;Papayannidis, Cristina
2018
Abstract
Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin.| File | Dimensione | Formato | |
|---|---|---|---|
|
s12885-018-5026-x.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
1 MB
Formato
Adobe PDF
|
1 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
